D. STOCKHOLDERS' EQUITY (Details 4) - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Number of Options Outstanding, Ending		241,735
2016 Plan
Number of Options Outstanding, Beginning		0
Number of Options Granted		50,000
Number of Options Cancelled		0
Number of Options Outstanding, Ending		50,000	0
Weighted Average Exercise Price Outstanding, Beginning		$ .00
Weighted Average Exercise Price Granted		6.10
Weighted Average Exercise Price Canceled		.00
Weighted Average Exercise Price Outstanding, Ending		$ 6.10	$ .00
Aggregate Intrinsic Value	[1]
1999 Plan
Number of Options Outstanding, Beginning		188,744	236,706
Number of Options Granted		3,000	13,000
Number of Options Cancelled		(9)	(60,962)
Number of Options Outstanding, Ending		191,735	188,744
Weighted Average Exercise Price Outstanding, Beginning		$ 95.24	$ 99.74
Weighted Average Exercise Price Granted		6.23	11.06
Weighted Average Exercise Price Canceled		2,760.00	94.75
Weighted Average Exercise Price Outstanding, Ending		$ 93.72	$ 95.24
Aggregate Intrinsic Value	[1]

[1] Amount represents the difference between the exercise price and $1.21, the closing price of Tenax Therapeutics' stock on December 31, 2018, as reported on the Nasdaq Capital Market, for all in-the-money options outstanding.